Cyprus Institute of Neurology and Genetics
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Cyprus Institute of Neurology and Genetics sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).
Cyprus Institute of Neurology and Genetics: 1 sponsored US clinical trial, 1 recruiting.
Cyprus Institute of Neurology and Genetics sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. The most-studied condition in this pipeline is Thalassemia Alpha, with 1 trials.
Mid-pack sponsor footprint
Cyprus Institute of Neurology and Genetics is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
1 total, page 1 of 1
Therapeutic Areas
What is open in the Cyprus Institute of Neurology and Genetics pipeline
1 recruiting of 1 indexed (100% open).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Thalassemia Alpha (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Cyprus Institute of Neurology and Genetics: open-pipeline peers nationwide
Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Cyprus Institute of Neurology and Genetics sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Cyprus Institute of Neurology and Genetics page
1 registered trials is a research-attention snapshot, not an endorsement of Cyprus Institute of Neurology and Genetics or any single study.
- 1 of Cyprus Institute of Neurology and Genetics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Thalassemia Alpha is the condition Cyprus Institute of Neurology and Genetics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Thalassemia Alpha trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Cyprus Institute of Neurology and Genetics pipeline card: 1 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.